Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of HLX14 versus Denosumab (Prolia) in postmenopausal osteoporosis at high fracture risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• HLX14
• Prolia (denosumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Postmenopausal | Phase 3 | Status: COMPLETED